Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A

doi:10.1084/jem.160.6.1792

This Article

	Full Text (PDF, 785K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Granelli-Piperno, A.
	Articles by Steinman, R. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Granelli-Piperno, A.
	Articles by Steinman, R. M.


Social Bookmarking

	What's this?

ARTICLES

Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A

A Granelli-Piperno, K Inaba and RM Steinman

Three-day, concanavalin A-induced T lymphoblasts have been used as a model to study lymphokine release from sensitized T cells. The blasts responded to interleukin 2 (IL-2) but did not constitutively produce this or other lymphokines. After mitogen restimulation, blast cells synthesized IL-2 as well as gamma-interferon, B cell-stimulating factor(s), and cytolytic differentiation factor(s). This production resulted from the induction of biologically active lymphokine mRNA. Cyclosporin A (CSA), a potent immunosuppressive agent, strongly inhibited synthesis of IL-2, gamma-interferon, and B cell- and CTL- stimulating factor(s), from mitogen-restimulated T blasts. In contrast, CSA did not block the cytolytic activity of the T blasts, nor modify bulk protein synthesis induced by Con A. CSA also blocked lymphokine release from a phorbol myristate acetate-stimulated thymoma cell line, EL-4. The effect of CSA was to block the induction of active lymphokine mRNA, as assayed in an oocyte translation system. This selective inhibition of lymphokine mRNA suggests that CSA may be useful in the therapy of inflammatory, lymphokine-mediated disease states.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Fretier, S., Besse, A., Delwail, A., Garcia, M., Morel, F., Leprivey-Lorgeot, V., Wijdenes, J., Praloran, V., Lecron, J.-C. (2002). Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production by activated human T lymphocytes. J. Leukoc. Biol. 71: 289-294 [Abstract] [Full Text]
Gerloni, V., Cimaz, R., Gattinara, M., Arnoldi, C., Pontikaki, I., Fantini, F. (2001). Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 40: 907-913 [Abstract] [Full Text]
Heitman, J, Movva, N., Hall, M. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909 [Abstract]
Khandke, L., Krane, J. F., Ashinoff, R., Staiano-Coico, L., Granelli-Piperno, A., Luster, A. D., Carter, D. M., Krueger, J. G., Gottlieb, A. B. (1991). Cyclosporine in Psoriasis Treatment: Inhibition of Keratinocyte Cell-Cycle Progression in G1 Independent of Effects on Transforming Growth Factor {alpha}/Epidermal Growth Factor Receptor Pathways. Arch Dermatol 127: 1172-1179 [Abstract]
LeGrue, S., Turner, R, Weisbrodt, N, Dedman, JR (1986). Does the binding of cyclosporine to calmodulin result in immunosuppression?. Science 234: 68-71 [Abstract]